Search for a doctor

Jason S. Starr, D.O.

  1. Hematologist / Oncologist

Publications

  1. Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, Kasi A, Barzi A, Samuelsz E, Karki A, Subramanian RA, Yemane D, Kim R, Wu CC, Croucher PJP, Smeal T, Kabbinavar FF, Lenz HJ. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. J Clin Oncol. 2024 Oct 30; JCO2401266 [Epub ahead of print]
    View PubMed
  2. Mosalem O, Coston TW, Imperial R, Mauer E, Thompson C, Yilma B, Bekaii-Saab TS, Stoppler MC, Starr JS. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer. Oncologist. 2024 Sep 6; 29 (9):e1224-e1227
    View PubMed
  3. Klatte DCF, Starr JS, Clift KE, Hardway HD, van Hooft JE, van Leerdam ME, Potjer TP, Presutti RJ, Riegert-Johnson DL, Wallace MB, Bi Y. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. JCO Oncol Pract. 2024 Aug; 20 (8):1081-1090 Epub 2024 Apr 15
    View PubMed
  4. Kusne Y, Lasho T, Finke C, Elsabbagh Z, McCue S, Hobday T, Starr J, Bekaii-Saab T, Halfdanarson TR, Patnaik MM, Ou FS, Sonbol MB. Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study. JCO Precis Oncol. 2024 Jun; 8:e2400143
    View PubMed
  5. McKinley BJ, Coston TW, Starr JS. Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. Oncologist. 2024 Mar 13 [Epub ahead of print]
    View PubMed
  6. Mosley SA, Cicali E, Del Cueto A, Portman DG, Donovan KA, Gong Y, Langaee T, Gopalan P, Schmit J, Starr JS, Silver N, Chang YD, Rajasekhara S, Smith JE, Soares HP, Clare-Salzler M, Starostik P, George TJ, McLeod HL, Fillingim RB, Hicks JK, Cavallari LH. CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial. Pharmacotherapy. 2023 Dec; 43 (12):1286-1296 Epub 2023 Sept 21
    View PubMed
  7. Andreatos N, McGarrah PW, Sonbol MB, Starr JS, Capdevila J, Sorbye H, Halfdanarson TR. Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment. Curr Oncol Rep. 2023 Oct; 25(10):1127-1139. Epub 2023 Aug 22.
    View PubMed
  8. Kasi PM, Bucheit LA, Liao J, Starr J, Barata P, Klempner SJ, Gandara D, Shergill A, Madeira da Silva L, Weipert C, Zhang N, Pretz C, Hardin A, Kiedrowski LA, Odegaard JI. Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 Sep; 7:e2300118
    View PubMed
  9. Mosalem O, Sonbol MB, Halfdanarson TR, Starr JS. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms. Best Pract Res Clin Endocrinol Metab. 2023 Sep; 37 (5):101796 Epub 2023 June 28
    View PubMed
  10. Pathak S, Starr JS, Halfdanarson T, Sonbol MB. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. 2023 Sep-Nov; 18 (5):377-385 Epub 2023 July 19
    View PubMed
  11. Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol. 2023 Aug 24; 14 (8):285-296
    View PubMed
  12. Coston T, Desai A, Babiker H, Sonbol MB, Chakrabarti S, Mahipal A, McWilliams R, Ma WW, Bekaii-Saab TS, Stauffer J, Starr JS. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. JCO Precis Oncol. 2023 Aug; 7:e2200706
    View PubMed
  13. Elhariri A, Starr JS, Bagaria S, Tran N, Babiker H. A Unicorn Disease: The Large Duct Variant of Invasive Ductal Adenocarcinoma of the Pancreas. Cureus. 2023 Jul; 15 (7):e41430 Epub 2023 July 05
    View PubMed
  14. Gococo-Benore DA, Kuhlman J, Parent EE, Sharma A, Accurso J, Yang M, Kendi AT, Johnson G, Sonbol MB, Hobday T, Halfdanarson TR, Starr J. Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden. J Nucl Med. 2023 Jun; 64 (6):880-884 Epub 2023 Apr 20
    View PubMed
  15. Gile JJ, McGarrah PW, Leventakos K, Sonbol MB, Starr JS, Eiring RA, Hobday TJ, Halfdanarson TR. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas. J Neuroendocrinol. 2023 May; 35 (5):e13283 Epub 2023 May 25
    View PubMed
  16. Wang J, Karime C, Majeed U, Starr JS, Borad MJ, Babiker HM. Targeting leukemia inhibitory factor in pancreatic adenocarcinoma. Expert Opin Investig Drugs. 2023 May; 32 (5):387-399 Epub 2023 Apr 24
    View PubMed
  17. Anisetti B, Coston TW, Ahmed AK, Mahadevia HJ, Edgar MA, Starr JS, Babiker HM. An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing. Cureus. 2023 Apr; 15 (4):e37239 Epub 2023 Apr 07
    View PubMed
  18. Alheraki SZ, Almquist DR, Starr JS, Halfdanarson TR, Sonbol MB. Treatment landscape of advanced high-grade neuroendocrine neoplasms. Clin Adv Hematol Oncol. 2023 Jan; 21 (1):16-26
    View PubMed
  19. Sonbol MB, Siddiqi R, Uson PLS, Pathak S, Firwana B, Botrus G, Almader-Douglas D, Ahn DH, Borad MJ, Starr J, Jones J, Stucky CC, Smoot R, Riaz IB, Bekaii-Saab T. The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis. Oncologist. 2022 Dec 9; 27 (12):1034-1040
    View PubMed
  20. Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Expert Opin Pharmacother. 2022 Dec; 23 (18):2079-2089 Epub 2022 Nov 28
    View PubMed
  21. Rutenberg MS, Hoppe BS, Starr JS, Awad Z, Thomas M, Morris CG, Johnson P, Henderson RH, Jones JC, Gharia B, Bowers S, Wolfsen HC, Krishnan S, Ko SJ, Babiker HM, Nichols RC Jr. Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes. Int J Part Ther. 2023 Winter; 9 (3):18-29 Epub 2022 Dec 19
    View PubMed
  22. Tofthagen C, Perlman A, Advani P, Ernst B, Kaur J, Tan W, Sheffield K, Crump J, Henry J, Starr J. Medical Marijuana Use for Cancer-Related Symptoms among Floridians: A Descriptive Study. J Palliat Med. 2022 Oct; 25 (10):1563-1570 Epub 2022 Aug 12
    View PubMed
  23. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022 Oct; 7 (5):100573 Epub 2022 Sept 07
    View PubMed
  24. Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, Cleary SP, Hobday T, Halfdanarson TR. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist. 2022 Jul 5; 27 (7):573-578
    View PubMed
  25. Chakrabarti S, Bucheit L, Starr JS, Innis-Shelton R, Shergill A, Dada H, Resta R, Wagner S, Fei N, Kasi PM. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022 Jun; 10 (6)
    View PubMed
  26. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
  27. Gococo-Benore DA, Parent E, Sharma A, Accurso J, Yang M, Kendi AT, Sonbol B, Halfdanarson TR, Starr JS. Hepatotoxicity from peptide receptor radionuclide therapy (prrt) in neuroendocrine tumors (nets) patients with very high liver tumor burden. Pancreas. 2022; 51(3):E47.
  28. Gococo-Benore DA, Boyle A, Wylie N, Drusbosky L, Khoor A, Starr JS. Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA. Cureus. 2022 Feb; 14 (2):e22276 Epub 2022 Feb 16
    View PubMed
  29. Tofthagen C, Tanay M, Perlman A, Starr J, Advani P, Sheffield K, Brigham T. A Systematic Review of Nutritional Lab Correlates with Chemotherapy Induced Peripheral Neuropathy. J Clin Med. 2022 Jan 12; 11 (2)
    View PubMed
  30. Wylie NS, Sokumbi O, Starr JS. Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor. JAMA Oncol. 2021 Dec 1; 7 (12):1891-1892
    View PubMed
  31. Starr JS, Skelton WP 4th, Rahmanian KP, Guenther R, Allen WL, George TJ, Moseley RE. Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients. J Palliat Care. 2021 Oct; 36 (4):211-218 Epub 2021 Mar 12
    View PubMed
  32. Tella SH, Starr JS, Kommalapati A, Sonbol MB, Halfdanarson TR. Management of well-differentiated neuroendocrine tumors. Clin Adv Hematol Oncol. 2021 Sep; 19 (9):582-593
    View PubMed
  33. Starr J, Puebla G, McMillan J, Lewis JT, Kasi PM. Microsatellite Instability-High, Malignant Insulinoma With Brain Metastasis. Cureus. 2021 Aug; 13 (8):e16969 Epub 2021 Aug 07
    View PubMed
  34. Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB, Kasi PM, Starr JS, Liu AJ, Nevala WK, Maus RL, Bois MC, Pitot HC, Chandrasekharan C, Ross HJ, Wu TT, Graham RP, Villasboas JC, Weiss M, Foster NR, Markovic SN, Dong H, Yoon HH. Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int J Cancer. 2021 Jul 15; 149 (2):378-386 Epub 2021 Mar 26
    View PubMed
  35. Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist. 2021 Jul; 26 (7):569-578 Epub 2021 Mar 05
    View PubMed
  36. Ueberroth BE, Liu AJ, Starr JS, Hobday TJ, Ashman JB, Mishra N, Bekaii-Saab TS, Halfdanarson TR, Sonbol MB. Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options. Clin Colorectal Cancer. 2021 Jun; 20 (2):e139-e149 Epub 2020 Dec 17
    View PubMed
  37. Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist. 2021 May; 26 (5):383-388 Epub 2021 Feb 08
    View PubMed
  38. Gile JJ, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. Pancreas. 2021 Apr 1; 50 (4):500-505
    View PubMed
  39. Botrus G, Uson Junior PLS, Raman P, Kaufman AE, Kosiorek H, Yin J, Fu Y, Majeed U, Sonbol MB, Ahn DH, Chang IW, Drusbosky LM, Dada H, Starr J, Borad M, Mody K, Bekaii-Saab TS. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Front Oncol. 2021; 11:794009 Epub 2022 Jan 10
    View PubMed
  40. Sonbol MB, Saad AM, Gonzalez-Velez M, Starr J, Halfdanarson TR. Causes of Death After Neuroendocrine Tumors Diagnosis: A US Population-Based Analysis. Pancreas. 2021 Jan 1; 50 (1):47-53
    View PubMed
  41. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020 Dec 1; 6 (12):e204930 Epub 2020 Dec 10
    View PubMed
  42. Rodriguez-Matta E, Hemmerich A, Starr J, Mody K, Severson EA, Colon-Otero G. Molecular genetic changes in solid pseudopapillary neoplasms (SPN) of the pancreas. Acta Oncol 2020 Sep; 59 (9):1024-1027 Epub 2020 July 16
    View PubMed
  43. Azar A, Devcic Z, Paz-Fumagalli R, Vidal LLC, McKinney JM, Frey G, Lewis AR, Ritchie C, Starr JS, Mody K, Toskich B. Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres. J Gastrointest Oncol. 2020 Aug; 11 (4):715-723
    View PubMed
  44. Zakka K, Nagy R, Drusbosky L, Akce M, Wu C, Alese OB, El-Rayes BF, Kasi PM, Mody K, Starr J, Shaib WL. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. Oncotarget. 2020 May 12; 11 (19):1749-1757
    View PubMed
  45. Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights. Onco Targets Ther. 2020; 13:3545-3555 Epub 2020 Apr 28
    View PubMed
  46. Starr J, Ramnaraign B. Germline BRCA1 mutated esophageal squamous cell carcinoma. Rare Tumors. 2020; 12:2036361320972218 Epub 2020 Nov 05
    View PubMed
  47. Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol. 2019 Dec; 10 (6):1099-1109
    View PubMed
  48. Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. JCO Precis Oncol. 2019 Dec; 3:1-9
    View PubMed
  49. Iqbal M, Roberts A, Starr J, Mody K, Kasi PM. Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. J Gastrointest Oncol. 2019 Jun; 10 (3):400-406
    View PubMed
  50. Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst. 2019 May 20 [Epub ahead of print]
    View PubMed
  51. Mody K, Kasi PM, Yang JD, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating tumor dna profiling of advanced biliary tract cancers JCO Precision Oncology. 2019 Mar 18; 3
  52. Hanayneh W, Parekh H, Fitzpatrick G, Feely M, George TJ, Starr JS. Two Cases of Rare Pancreatic Malignancies. J Pancreat Cancer. 2019; 5 (1):26-33 Epub 2019 July 23
    View PubMed
  53. Yuan C, Parekh H, Allegra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardiooncology. 2019; 5:13 Epub 2019 Sept 06
    View PubMed
  54. Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials. 2018 May; 68:7-13 Epub 2018 Mar 10
    View PubMed
  55. Franke AJ, Parekh H, Starr JS, Tan SA, Iqbal A, George TJ Jr. Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management. Clin Colorectal Cancer. 2018 Mar; 17 (1):1-12 Epub 2017 June 27
    View PubMed
  56. Skelton WP 4th, Parekh H, Starr JS, Trevino J, Cioffi J, Hughes S, George TJ Jr. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. J Gastrointest Cancer. 2018 Mar; 49 (1):1-8
    View PubMed
  57. Parekh HD, Starr J, George TJ Jr. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Curr Treat Options Oncol. 2017 Nov 16; 18 (12):73
    View PubMed
  58. Bajwa R, Starr J, Daily K. Gemcitabine-induced chronic systemic capillary leak syndrome. BMJ Case Rep. 2017 Aug 30; 2017
    View PubMed
  59. Davila JI, Starr JS, Attia S, Wang C, Knudson RA, Necela BM, Sarangi V, Sun Z, Ren Y, Casler JD, Menke DM, Oliver GR, Joseph RW, Copland JA, Parker AS, Kocher JA, Thompson EA, Smallridge RC, Asmann YW. Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. Rare Tumors. 2017 Jul 3; 9 (2):6834 Epub 2017 Sept 15
    View PubMed
  60. Franke AJ, Iqbal A, Starr JS, Nair RM, George TJ Jr. Management of Malignant Bowel Obstruction Associated With GI Cancers. J Oncol Pract. 2017 Jul; 13 (7):426-434
    View PubMed
  61. Advani P, Starr J, Swaika A, Jiang L, Qiu Y, Li Z, Tun HW. T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma. Rare Tumors. 2015 Dec 29; 7 (4):6084
    View PubMed
  62. Starr JS, Attia S, Joseph RW, Menke D, Casler J, Smallridge RC. Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass. J Clin Oncol. 2015 Jun 10; 33 (17):e74-6 Epub 2014 Mar 24
    View PubMed
  63. Starr JS, Jiang L, Li Z, Qiu Y, Menke DM, Tun HW. CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13 (5):597-601 Epub 2013 June 26
    View PubMed
  64. Park CK, Li X, Starr J, Harris EE. Cardiac morbidity and mortality in women with ductal carcinoma in situ of the breast treated with breast conservation therapy. Breast J. 2011 Sep-Oct; 17(5):470-6. Epub 2011 Jul 15.
    View PubMed
PST-20439447